Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfacon-2 in Chronic Hepatitis B
NCT06544551Phase 3Completed
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Peginterferon Alfacon-2 + TAF with Placebo + TAF (2 arms). Primary endpoint: Proportion of patients with HBsAg negative at 72 weeks. Started Dec 2021; status: completed.
02
Drugs
peginterferon alfacon-2
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06544551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544551.